ACHV net incomeQ2 2026-$74.77M
ACHV net income was -$74.77M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$12.72M a year earlier. For the full fiscal 2025 it was -$54.65M, compared with -$39.83M in fiscal 2024.
Achieve Life Sciences Inc. (ACHV) financials
For the twelve months ended Jun 30, 2026, Achieve Life Sciences Inc. reported -$114.04M of net income.
- Net income, TTM
- -$114.04M
- Cash
- $47.96M
- Market cap
- $691.0M
FY2018FY2019
FY2016FY2025
FY2016FY2025
ACHV revenue and earnings growth
ACHV EPSQ2 2026-$0.80
ACHV diluted EPS was -$0.80 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.25, compared with -$1.24 in fiscal 2024.
ACHV free cash flowFY2025-$49.47M
ACHV free cash flow was -$49.47M for fiscal 2025 (ended Dec 31, 2025).
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | - | - |
| Research and development | - | $22.82M | $15.81M | $30.08M | $23.97M | $6.88M | $9.67M | $5.87M | $3.10M | $286.0K |
| Selling, general and admin | - | $16.25M | $11.44M | $10.72M | $9.13M | $7.87M | $6.85M | $6.95M | $3.53M | $1.43M |
| Interest expense | $819.0K | $2.18M | $2.85M | $1.79M | - | - | - | - | - | - |
| Pre-tax income | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M | -$14.73M | -$16.39M | -$12.69M | -$13.63M | -$1.74M |
| Income tax | - | - | - | - | - | - | - | - | - | $0 |
| Net income | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M | -$14.73M | -$16.39M | -$12.69M | -$10.58M | -$1.23M |
| EPS, basic | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | -$39.76 | -$72.29 | -$441.40 | -$11625.00 |
| EPS, diluted | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | -$39.76 | -$72.29 | -$441.40 | -$11625.00 |
| Diluted shares | 43.6M | 32.1M | 19.8M | 10.6M | 8.1M | 2.7M | 412,320 | 175,511 | 23,972.1 | 106.15 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.93M | $12.75M | $15.55M | $24.77M | $43.02M | $35.85M | $16.66M | $9.52M | $5.28M | $15.0K |
| Short-term investments | $15.47M | $21.61M | - | - | - | - | - | $5.09M | - | $10.23M |
| Receivables | - | - | - | - | - | - | $8.0K | $7.0K | $9.0K | $478.0K |
| Current assets | $39.89M | $36.47M | $16.98M | $27.33M | $44.59M | $36.98M | $17.33M | $15.54M | $5.91M | $18.0K |
| Goodwill | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M |
| Total assets | $41.79M | $38.63M | $19.37M | $29.97M | $47.52M | $40.30M | $21.08M | $19.08M | $9.89M | $3.81M |
| Current liabilities | $9.08M | $6.68M | $20.81M | $21.60M | $4.55M | $2.94M | $2.87M | $3.27M | $2.01M | $3.07M |
| Total liabilities | $20.27M | $17.73M | $20.82M | $21.67M | $19.47M | $3.01M | $3.03M | $3.28M | $2.01M | $3.20M |
| Shareholders' equity | $21.52M | $20.90M | -$1.45M | $8.30M | $28.04M | $37.29M | $18.05M | $15.80M | $15.80M | $610.0K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.47M | -$29.77M | -$24.48M | -$37.57M | -$29.44M | -$13.47M | -$15.22M | -$10.62M | -$9.11M | -$202.0K |
| Capital expenditures | $3.0K | - | $21.0K | - | - | $17.0K | $53.0K | $46.0K | - | $46.0K |
| Free cash flow | -$49.47M | - | -$24.50M | - | - | -$13.49M | -$15.27M | -$10.67M | - | -$248.0K |
| Investing cash flow | $6.11M | -$21.58M | -$21.0K | - | - | -$17.0K | $5.04M | -$5.13M | $12.65M | $10.61M |
| Financing cash flow | $51.53M | $48.53M | $15.28M | $19.32M | $36.61M | $32.68M | $17.32M | $19.76M | $2.00M | $150.0K |
| Stock-based compensation | $8.76M | $5.33M | $3.44M | $3.27M | $2.19M | $1.29M | $1.20M | $854.0K | $348.0K | $1.65M |
| Depreciation and amortization | $228.0K | $229.0K | $228.0K | $236.0K | $250.0K | $255.0K | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -254.0% | -190.6% | - | -510.1% | -118.2% | -39.5% | -90.8% | -80.3% | -67.0% | -202.3% |
| Return on assets | -130.8% | -103.1% | -153.9% | -141.3% | -69.8% | -36.6% | -77.8% | -66.5% | -107.0% | -32.4% |
| Current ratio | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.75 | 2.93 | 0.01 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | - | - | $5.32M | $6.71M | $7.10M | $7.30M | $7.61M | $5.11M | $2.80M | $2.11M | $3.58M |
| Selling, general and admin | - | - | - | $9.37M | $5.86M | $5.80M | $4.89M | $4.86M | $3.32M | $3.18M | $2.27M | $2.99M |
| Interest expense | $277.0K | $274.0K | $251.0K | $192.0K | $191.0K | $185.0K | $197.0K | $366.0K | $804.0K | $813.0K | $787.0K | $781.0K |
| Net income | -$74.77M | -$10.17M | -$14.66M | -$14.44M | -$12.72M | -$12.83M | -$12.36M | -$12.51M | -$8.46M | -$6.49M | -$5.48M | -$7.11M |
| EPS, basic | -$0.80 | -$0.19 | - | -$0.28 | -$0.37 | -$0.37 | - | -$0.36 | -$0.25 | -$0.26 | -$0.23 | -$0.34 |
| EPS, diluted | -$0.80 | -$0.19 | - | -$0.28 | -$0.37 | -$0.37 | - | -$0.36 | -$0.25 | -$0.26 | -$0.23 | -$0.34 |
| Diluted shares | 93.5M | 53.4M | - | 51.0M | 34.7M | 34.7M | - | 34.4M | 34.3M | 25.0M | - | 21.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $47.96M | $28.08M | $20.93M | $31.93M | $51.87M | $13.02M | $12.75M | $9.54M | $14.76M | $66.40M | $15.55M | $19.92M |
| Short-term investments | $139.34M | $1.19M | $15.47M | $16.18M | $3.52M | $10.23M | $21.61M | $33.37M | $46.56M | - | - | - |
| Current assets | $188.29M | $31.06M | $39.89M | $50.05M | $56.90M | $25.00M | $36.47M | $45.53M | $62.52M | $67.71M | $16.98M | $21.90M |
| Goodwill | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M |
| Total assets | $190.44M | $33.10M | $41.79M | $52.04M | $58.94M | $27.36M | $38.63M | $47.92M | $64.79M | $70.03M | $19.37M | $24.34M |
| Current liabilities | $197.66M | $11.83M | $9.08M | $9.73M | $8.57M | $7.13M | $6.68M | $6.72M | $13.70M | $20.57M | $20.81M | $4.08M |
| Total liabilities | $205.12M | $22.43M | $20.27M | $18.43M | $17.27M | $17.08M | $17.73M | $16.54M | $22.51M | $20.57M | $20.82M | $20.30M |
| Shareholders' equity | -$14.68M | $10.68M | $21.52M | $33.62M | $41.67M | $10.28M | $20.90M | $31.38M | $42.28M | $49.46M | -$1.45M | $4.04M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.78M | -$6.93M | -$17.98M | -$11.33M | -$9.07M | -$11.09M | -$9.19M | -$10.37M | -$4.92M | -$5.29M | -$4.36M | -$5.14M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $6.0K | - |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$4.37M | - |
| Investing cash flow | -$137.80M | $14.28M | $709.0K | -$12.65M | $6.70M | $11.35M | $11.72M | $13.27M | - | - | -$6.0K | - |
| Financing cash flow | $168.46M | $21.0K | $6.26M | $4.04M | - | - | $682.0K | -$8.11M | -$153.0K | $56.11M | $0 | $0 |
| Stock-based compensation | $6.96M | -$685.0K | $1.30M | $2.34M | $2.89M | $2.23M | $1.24M | $1.34M | $1.45M | $1.29M | -$10.0K | $1.17M |
| Depreciation and amortization | $58.0K | $57.0K | $57.0K | $54.0K | $55.0K | $62.0K | $58.0K | $57.0K | $57.0K | $57.0K | $57.0K | $58.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.95 | 2.62 | 4.39 | 5.14 | 6.64 | 3.51 | 5.46 | 6.78 | 4.56 | 3.29 | 0.82 | 5.36 |
Source: XBRL data Achieve Life Sciences Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 7, 2018; 1-for-20, first reported Aug 6, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ACHV peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ACHV | - | - | -$114.04M | - | $691.0M |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $53.26B |
| ORKA | - | - | -$132.89M | - | $6.81B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.57B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.57B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.35B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.59B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $733.5M |
| MYGN | $803.60M | -2.6% | -$129.10M | -16.1% | $565.8M |
ACHV FAQ
4 questionsIs ACHV profitable?
No. Achieve Life Sciences Inc. reported a net loss of $114.04M for the twelve months ended Jun 30, 2026.How much cash and debt does ACHV have?
Achieve Life Sciences Inc. reported $47.96M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did ACHV last report financial results?
The latest statements here come from Achieve Life Sciences Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this ACHV financial data come from?
Quantisnow builds these statements from the structured XBRL data Achieve Life Sciences Inc. files with the SEC. It is provided for information only and is not investment advice.